Protease Inhibitor and Metabolic Alteration

DOI : http://dx.doi.org/10.4067/S0717-95022012000200014
Tweet about this on TwitterShare on FacebookEmail this to someoneShare on Google+

Cavenaghi, F. M.; Bataglion, C. A. N.; Paula, P. C.; Motta, A. C. F. & Komesu, M. C.

Summary

Protease inhibitors (PIs), part of HAART (Highly Active Antiretroviral Therap) are selective, competitive inhibitors of protease, a crucial enzyme to viral maturation, infection and replication. A lipodystrophic syndrome has been reported in individuals treated with HAART, and associated to hyperglycemia, hypercholesterolemia, hypertrigliceridemia, hyperlipidemia, hypertension and hypreinsulinemia. The HAART-associated metabolic abnormalities were first associated with protease inhibitors, Ritonavir mostly, but the mechamisns that underlie these metabolic alterations are to date, not completely understood. Since PIs are candidate to be the drug of choice for other diseases treatment, such as the Hepatitis C, malaria and some types of cancer, it seems to be important to clarify the metabolic alterations associated to PIs. Wistar rats were treated twice a week with 30mg/kg Ritonavir for 4 and 8 weeks. Total cholesterol, HDL, LDL, VLDL, triglycerides and glycemic levels were measured by the end of each period of time selected. To avoid confunding effects of food intake, the animals were fasted 16 hours before. Our results showed rapid increase in serum triglycerides, total cholesterol, LDL-C and glycemic levels. No significant differences were observed for HDL-C or VLDL serum levels. Our study addresses the importance to observe the possible family history of dyslipidemia or diabetes, and control any other cardiovascular and diabetes risk factors when using protease inhibitors

KEY WORDS: Protease inhibitors; Dyslipidemia; Metabolic disorders.

How to cite this article

CAVENAGHI, F. M.; BATAGLION, C. A. N.; PAULA, P. C.; MOTTA, A. C. F. & KOMESU, M. C. Protease inhibitor and metabolic alteration. Int. J. Morphol., 30(2):439-444, 2012.